Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dignical is a multi-ingredient nutritional supplement developed and marketed by Rowez Life Sciences. It is formulated to support bone health and treat mineral deficiencies, typically containing a combination of calcium citrate, cholecalciferol (Vitamin D3), magnesium hydroxide, and zinc sulfate. Calcium citrate provides a bioavailable source of calcium for bone mineralization, while cholecalciferol acts as an agonist at the Vitamin D receptor (VDR) to enhance intestinal calcium and phosphorus absorption. Magnesium and zinc are included as essential minerals that serve as cofactors for various enzymes involved in bone formation and maintenance. Dignical is primarily indicated for the prevention and treatment of osteoporosis, osteomalacia, and other conditions associated with calcium and Vitamin D deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dignical.